Multiple Myeloma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Myeloma stocks.

Multiple Myeloma Stocks Recent News

Date Stock Title
Oct 31 BMY Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
Oct 31 BMY Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
Oct 31 BMY Bristol Myers Screams To A Year-High After Walloping Profit Expectations
Oct 31 BMY Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
Oct 31 BMY Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Oct 31 BMY Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
Oct 31 BMY Bristol-Myers Squibb in charts: Q3 revenue from Eliquis, Opdivo, Yervoy rises, Sprycel falls
Oct 31 BMY Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
Oct 31 BMY Bristol-Myers raises outlook ahead of consensus after Q3 beat
Oct 31 BMY Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up
Oct 31 BMY Bristol Myers earnings beat expectations, driven by sales of older drugs
Oct 31 BMY Bristol Myers: Q3 Earnings Snapshot
Oct 31 BMY Bristol-Myers Squibb Company  Non-GAAP EPS of $1.80 beats by $0.30, revenue of $11.89B beats by $640M
Oct 31 BMY Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
Oct 30 BMY Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated
Oct 30 BMY Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’
Oct 29 BMY Zai Lab reports positive Chinese study data for KarXT for schizophrenia
Oct 29 BMY Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
Multiple Myeloma

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Often, no symptoms are noticed initially. When advanced, bone pain, bleeding, frequent infections, and anemia may occur. Complications may include amyloidosis.The cause is unknown. Risk factors include obesity, radiation exposure, family history, and certain chemicals. The underlying mechanism involves abnormal plasma cells producing abnormal antibodies which can cause kidney problems and overly thick blood. The plasma cells can also form a mass in the bone marrow or soft tissue. When only one mass is present, it is known as a plasmacytoma, while more than one is known as multiple myeloma. Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibodies, bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. Another common finding is high blood calcium levels.Multiple myeloma is considered treatable, but generally incurable. Remissions may be brought about with steroids, chemotherapy, targeted therapy, and stem cell transplant. Bisphosphonates and radiation therapy are sometimes used to reduce pain from bone lesions.Globally, multiple myeloma affected 488,000 people and resulted in 101,100 deaths in 2015. In the United States, it develops in 6.5 per 100,000 people per year and 0.7% of people are affected at some point in their lives. It usually occurs around the age of 61 and is more common in men than women. It is uncommon before the age of 40. Without treatment, typical survival is seven months. With current treatments, survival is usually 4–5 years. This gives a five-year survival rate around 49%. The word myeloma is from the Greek myelo- meaning "marrow" and -oma meaning "tumor".

Browse All Tags